PD-1 inhibitor pembrolizumab and nivolumab were the only allowed ICI for recurrent/metastatic (R/M) HNSCC in the clinical, and the patients could get more therapeutic benefits from it, like longer OS compared with standard chemotherapy (7). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.